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Abstract
Background: In the last decade hepatitis E virus (HEV) is increasingly recognized as a cause of acute viral hepatitis
in developed countries. HEV is transmitted via the fecal-oral route. In countries like the Netherlands, HEV infection is
suspected to be a zoonosis but HEV may also be introduced by migrants. We studied the seroprevalence of HEV
among different migrants, mainly Moroccans and Turks, and compared this to that of the native Dutch population
in Amsterdam, the Netherlands.
Methods: Data were obtained from a cross-sectional survey of the adult Amsterdam population performed in 2004;
the Amsterdam Health Monitor. A total of 1199 plasma samples were tested for IgG-and IgM antibodies to HEV
using the Wantai kit according to instructions of the manufacturer. Basic demographic data (gender, age, country
of birth, and age at immigration) were used in the analyses. Hepatitis A virus (HAV) serology data were available
from a previous study.
Results: The total weighted anti-HEV IgG seroprevalence in the overall Amsterdam population was 26.7 %, based
on 1199 samples. In the study population (not-weighted) this HEV seroprevalence was 157/426 (36.9 %) for the
Dutch participants and it was 161/257 (62.6 %) for Moroccans, 99/296 (33.4 %) for Turks and 42/220 (19.1 %) for
other ethnicities. HEV seroprevalence increased significantly with age. First-generation Moroccan migrants (44.0 %)
had a significantly higher weighted HEV seroprevalence than the Dutch participants (29.7 %). In the first generation
Turks (20.3 %) and first generation migrants from other countries (16.7 %) this weighted seroprevalence was lower,
but this was only significant for the ‘other ethnicities’. The median age of migration was significantly higher in the
Moroccan and Turkish migrants who were HEV IgG positive versus HEV IgG negative. However, when stratifying for
age at time of study, median migration age was only significantly different for HEV sero-status for younger Turks
and younger ‘other ethnicities’. HEV IgM antibodies were found in 0.6 % (n = 7) of participants and none were
positive for HEV RNA, showing that there were no acute infections. Despite the common route of fecal-oral
transmission for both viruses, there was no relation between HEV and HAV seropositivity.
Conclusion: Within the multi-ethnical capital city of Amsterdam the HEV seroprevalence in first generation migrant
populations differed from each other and from the autochthonous Dutch population. The relation between being
HEV seropositive and a higher median age of migration suggests that younger migrants got more often infected in
their country of origin than in the Netherlands.
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Background
Since 1980, hepatitis E virus (HEV) is recognized as a
causative agent of acute viral inflammation of the human
liver [1]. The clinical features resemble those of infection
with hepatitis A virus (HAV), and both are transmitted by
the fecal-oral route or by contaminated water [2]. Unlike
HAV, secondary transmission appears to be of minor sig-
nificance [3, 4]. HEV infection is usually self-limited, and
its severity may range from subclinical infection to fulmin-
ant liver failure, probably depending on genotype. The risk
for a fulminant disease course is particularly high in preg-
nant women, with an increased risk for adverse pregnancy
outcomes and a maternal mortality rate up to 20 % in case
of a genotype 1 infection [5–7]. In addition, an increased
risk for complications is observed in immunosuppressed
persons, especially in transplant patients who may develop
chronic hepatitis [8, 9].
HEV, a non-enveloped single-stranded RNA virus, is
classified as a unique member of genus Hepevirus in the
family of Hepeviridiae, of which only one serotype is
known [10]. Four human HEV genotypes have been
identified, each having distinct geographical distribu-
tions. Genotypes 1 and 2 are responsible for large water-
borne HEV outbreaks in humans in tropical and sub-
tropical parts of Asia, Africa and Central America due
to poor hygiene. In these areas HEV infection is consid-
ered an important cause of acute clinical hepatitis in
adults [11, 12]. In developed Western countries HEV
genotypes 3 and 4 are thought to be zoonotic as they are
found in domestic pigs and cows and also in wild
animals such as swine, deer, and mongoose [13]. The
exact route of transmission of genotypes 3 and 4 is still
unknown, but it may be by eating contaminated under-
cooked food such as meat from domestic pigs, or from
wild animals [12–15].
In the Netherlands, the incidence of HEV is unknown,
and representative data on the seroprevalence of HEV
antibodies in the general Dutch population are scarce. In
2011 it was estimated that on average 27 % of Dutch
blood donors were anti-HEV IgG positive, with an age-
dependent increase from 13 % in teenagers to 42 % in
those of 50 years and older [16].
This study investigated a representative sample of the
general adult population of Amsterdam, the Netherlands,
on the presence of antibodies against HEV in relation to
demographic data. Amsterdam has large migrant commu-
nities, mainly from Morocco and Turkey, but also from
people originating from various tropical countries such as
Surinam, Netherlands Antilles and Indonesia. This
allowed us to look for determinants for anti-HEV sero-
positivity in different migrant groups using data and sam-
ples from a study that was performed in 2004, the
Amsterdam Health Monitor (AHM). Furthermore, we
looked whether anti-HEV seropositivity was related to the
seroprevalence of hepatitis A virus (HAV) in the same
AHM population [17]. The resulting data offers new in-
sights into the sero-epidemiology of HEV infection in an
urbanized area with mixed ethnicities.
Methods
Study population and sampling procedure
The data used for this study were obtained from a cross-
sectional survey, the Amsterdam Health Monitor
(AHM) study, carried out in 2004 by the Public Health
Service of Amsterdam (GGD Amsterdam) and was ap-
proved by the Medical Ethics Committee of the Aca-
demic Medical Centre in Amsterdam, the Netherlands.
A random sample of residents aged 18 years or older
was selected from the municipal register in Amsterdam.
The sample was stratified by age and ethnicity, with
oversampling of Turkish and Moroccan persons. After
providing written informed consent, participants were
interviewed and gave blood samples. Within 48 h the
plasma samples were stored at −80 °C. Of those inter-
viewed, 79 % (n = 1376) provided blood samples of
whom 1294 (94 %) plasma samples were available for
HEV antibody testing. Of these, 1199 (93 %) samples
from Dutch participants and first generation migrants
were included in the statistical analyses. Further details
of the AHM study population are described by Agye-
mang et al., 2006, and in other studies [17–19].
For this study, the participants were classified into four
ethnic groups: Dutch, Turkish, Moroccan, and ‘other’, ac-
cording to the self-reported country of birth of the par-
ticipant’s mother. If the mother was born in the
Netherlands or country of birth was unknown, the self-
reported country of birth of the participant’s father was
used. All participants of non-Dutch ethnic origin were
classified as first (born outside the Netherlands)- or sec-
ond (born in the Netherlands)-generation migrants. The
second generation participants were excluded in this
study, because of small numbers (n = 87) and the fact
that their ethnicities were very diverse.
Laboratory testing
Plasma samples from participants were tested for anti-
bodies to HEV (anti-HEV IgG, anti-HEV IgM) by means
of an enzyme immunoassay according to instructions of
the manufacturer (Wantai Biological Pharmacy Enter-
prise Co., Ltd , Beijing, China). Antibodies to HAV were
tested as described elsewhere [17].
Reverse transcriptase PCR was performed to detect HEV
RNA according to a previously published protocol [16].
Statistical analysis
To make the results representative for the adult popula-
tion in Amsterdam, prevalences and 95 % confidence in-
tervals (95 % CI), were calculated using the weighted
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population fraction and complex samples module of
SPSS. The data were weighted for age, sex, and ethnic
origin, by correcting for the oversampling by ethnic
groups as previously described [18]. Prevalences were
calculated and compared using Chi-squared test.
Univariable and multivariable logistic regression with
backward selection method were used to test for the as-
sociation between demographic covariates and HEV
seropositivity. Differences between HEV IgG seropositive
and seronegative groups with respect to median age of
migration was calculated per ethnicity using the Mann–
Whitney U test. Values of p < 0.05 were considered
significant. Calculations were performed in SPSS, version
20 (SPSS Inc., Chicago, Illinois, USA).
Results
Characteristics of the study sample
The study sample of 1199 participants consisted of 558
men (46.5 %) and 641 women (53.5 %) (Table 1). Age
ranged from 18 to 90 years. The median age for men
was 51 years (IQR 19 years) and for women 49 years
(IQR 20 years). Most participants were Dutch (35.5 %)
and almost all 753 first generation migrant participants
came from Turkey (296; 24.7 %) or Morocco (257;
21.4 %), due to deliberate oversampling among Turkish
and Moroccan populations. Most ‘others’ came from the
Republic of Surinam (n = 60) or the Netherlands Antilles
(n = 11). Participants were equally distributed over the
sexes, except for Moroccans, of whom 58.4 % was male,
and for Dutch participants, of whom 58.9 % were
women. The median age at migration was 25 years
(range 0–76 years), and only a minority (8 %) migrated
to the Netherlands before the age of 15 years.
Seroprevalence and determinants of anti-HEV in the
Amsterdam population
Seven of the 1199 available plasma samples (0.6 %)
tested positive for anti-HEV IgM, and none of them
were HEV RNA positive. This indicates that there were
no or very few acute HEV infections. The 7 samples
were from 4 Dutch participants, one Moroccan, one
Turkish, and one participant from former Yugoslavia.
Of 1199 plasma samples 459 (38.2 %) tested positive
for anti-HEV IgG. The HEV seroprevalence is shown in
Table 1, both non-weighted, representing the study sam-
ple, and weighted, representing the Amsterdam popula-
tion. The weighted anti-HEV IgG seroprevalence in the
total Amsterdam population in the year 2004 was 26.7 %
(95 % CI 23.8–29.8 %). The weighed anti-HEV IgG sero-
prevalence increased from 9.8 % in the youngest age cat-
egory (18 to 34 years) to 54.4 % in the oldest age group
(older than 65 years).
In univariable analysis, anti-HEV IgG was associated
with gender, age and ethnic origin (Table 1). Women
were significantly less likely to be anti-HEV positive
compared to men. In multivariable analysis, age and eth-
nic origin remained independent predictors for anti-
HEV IgG seropositivity.
Table 1 Prevalence of anti- HEV IgG in association with demographic characteristics in the adult Amsterdam population in 2004
Characteristic Study sample Amsterdam adult population
Total
tested







No. (%) P value P value %
Total 1199 459 (38.3) 26.7 (23.8–29.8)
Gender 0.002 0.54
Male 558 239 (42.8) 1 26.0 (22.0–31.1)
Female 641 220 (34.3) 0.7 (0.6–0.9) 27.0 (23.2–31.1)
Age category <0.001 <0.001
18–34 162 15 (9.3) 1 1 9.8 (5.5–17.0)
35–44 269 64 (23.8) 3.1 (1.7–5.6) 3.0 (1.6–5.5) 20.7 (15.1–27.7)
45–54 308 124 (40.3) 6.6 (3.7–11.8) 7.5 (4.2–13.7) 33.3 (27.2–40.1)
55–64 257 135 (52.5) 10.8 (6.0–19.5) 11.7 (6.4–21.5) 42.7 (35.3–50.4)
65 and older 203 121 (59.6) 14.5 (7.9–26.4) 18.1 (9.7–33.8) 54.4 (45.8–62.8)
Ethnic origin <0.001 <0.001
Dutch 426 157 (36.9) 1 1 29.7 (25.7–34.0)
Moroccan 257 161 (62.6) 2.9 (2.1–4.0) 3.5 (2.4–4.9) 44.0 (37.1–51.1)
Turkish 296 99 (33.4) 0.9 (0.6–1.2) 1.1 (0.8–1.5) 20.3 (17.0–24.0)
Otherb 220 42 (19.1) 0.4 (0.3–0.6) 0.4 (0.3–0.6) 16.9 (12.0–23.3)
aThe weighted seroprevalence was calculated, taking fractions of ethnical residents in Amsterdam into account, as explained in Methods
bOther countries are mainly Surinam, Netherlands Antilles and Indonesia
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The weighted seroprevalence was highest among
first-generation Moroccan migrants (44.0 %) and they
were significantly more often anti-HEV IgG positive
compared to those of Dutch ethnic origin with a
seroprevalence of 29.7 % (OR 3.5; 95 % CI 2.4–4.9).
The weighted seroprevalence of anti-HEV IgG in
first-generation Turkish migrants was 20.3 % which
did not differ significantly from the Dutch (OR 1.1;
95 % CI 0.8–1.5). From ‘other’ countries the weighted
HEV seroprevalence was 16.9 % which was in multi-
variate analysis significantly lower than the seropreva-
lence in the Dutch population (Table 1).
We examined the relation between age of migration
and being seropositive for HEV. Significant differences
were seen for both the Moroccan and Turkish
groups, with a higher median migration age of those
who were HEV IgG positive versus HEV IgG negative
(Table 2). Since HEV positivity was found to increase
with age, we also compared the median ages of mi-
gration in stratified groups per ethnicity. The stratifi-
cation was made with the median age of participation
as cut-off. The differences were no longer significant
for the Moroccan groups, with comparable ages of
migration in the ‘younger’ and ‘older’ participants
(Table 2). For the Turks however, the median age of
migration in the ‘younger’ group was significantly
higher in the HEV IgG positive group (24 years) than
in the HEV IgG negative group (18 years). Also in
the ‘other ethnicities’ the median age of migration in
the younger group was significantly higher in the
HEV IgG positive (27 years) versus the HEV IgG
negative (23 years) group (Table 2). This indicates in
‘younger’ immigrant (except Moroccans) that those
who migrated at a younger age to the Netherlands
were less likely to be HEV infected.
Anti-HAV status
The HAV IgG status was known from a previous study
[17] and was available for all 1199 samples. Those who
were HAV IgG positive were compared for two sub-
groups: participants who were anti-HEV IgG positive
and anti-HEV IgG negative (Table 3). Of the 459 anti-
HEV seropositive persons 374 (81.5 %) had also anti-
bodies for HAV. This was not significantly different in
the anti-HEV IgG seronegative group (73.1 %). For the
Dutch participants with 48.4 % HAV IgG seropositive
there was also no significant difference in HAV status in
relation to anti-HEV seropositivity. Almost all first
generation migrants from Morocco and Turkey (97.7 to
99.3 %) were HAV seropositive, regardless of their anti-
HEV IgG status (Table 3). For the ‘other ethnicities’
there were also no significant differences between the
two groups for anti-HEV IgG status. This indicates that
there is no association between infection with HEV and
infection with HAV in these populations.
Discussion
In this cross-sectional study among the adult population
of Amsterdam, we found clear differences in HEV sero-
prevalence between those born in the Netherlands and
first generation migrants. This has not been reported be-
fore within one multi-ethnic population. Also new in
this study is that weighted calculations could be made in
the AHM study. The overall weighted seroprevalence of
HEV-IgG in the adult Amsterdam population was
26.7 % in 2004, which is comparable to an estimate
made in 2011 among Dutch blood donors (27 %) by Slot
et al. [16]. Yet the blood donor population likely reflects
a more autochthonous Dutch population with certainly
less Moroccans and Turkish participants, as in the AHM
study a deliberate oversampling on these ethnicities was
Table 2 Relation between hepatitis E virus IgG and median age of migration per ethnicity of first generation migrants
Ethnicity Stratification by
median age (years)a
HEV IgG Negative HEV IgG positive P valued
N Median age of migrationb (SD) N Median age of migrationb (SD) Missingc N
Moroccan none 95 26 (11.0) 154 27 (9.4) 8 0.021
≤51 68 21 (11.7) 55 23 (8.7) 3 0.310
>51 27 29 (6.0) 99 29 (8.7) 5 0.493
Turkish none 195 23 (9.5) 97 29 (8.5) 4 <0.001
≤46 122 18 (7.7) 22 24 (7.6) 1 0.003
>46 73 29 (8.3) 75 30 (8.1) 3 0.321
Other none 173 25 (13.3) 38 27 (10.1) 9 0.367
≤50 82 23 (9.7) 18 27 (7.7) 4 0.028
>50 91 28 (14.9) 20 27 (12.1) 5 0.466
Differences in median migration ages between HEV IgG negative and HEV IgG positive groups were tested using the Mann–Whitney U test
aMedian age of participants at the time of the study
bMedian age at which participants migrated to the Netherlands
cMissing: no data available on age of migration
dNumbers in bold indicate significant differences
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performed. Similar to the blood donor population our
study demonstrated an age related increase of anti-HEV
seroprevalence of 10 % in those younger than 35 years,
to 55 % in persons of 65 years and older. This associ-
ation of HEV-IgG seropositivity with increasing age has
also been reported in other studies [20–23]. In the
Netherlands, the anti-HEV seroprevalence in blood
donor populations declined over time from 46.6 % in
1988 to 20.9 % in 2011 among comparable age groups,
indicating that the HEV infection pressure is not
constant. Indeed, in the Netherlands a recent rise of
anti-HEV IgG prevalence among young blood donors in-
dicates that the HEV incidence is increasing again [21].
First generation migrants of Moroccan ethnic origin
were 3 times more likely to be anti-HEV-seropositive
compared to the autochthonous Dutch population. A re-
cent review reported that the anti-HEV seroprevalence
in the general population in countries of the Middle East
and the Northern African-region, where also Morocco is
situated, ranges from 2 to 38 % [24]. This is lower than
the 44 % weighted prevalence that we found among first
generation Moroccans in Amsterdam.
There was a significant difference in age of migration
between those who were HEV positive versus HEV
negative in the ‘younger’ Turkish and ‘other’ ethnicity
migrants, but not for the Moroccans. This could indicate
that those who migrated at an older age from Turkey or
the other countries had got infected in the country of
origin. Those who were older than 40 to 45 years at the
time of study participation had been at least 20 years in
the Netherlands (Table 2) and had experienced an equal
infection pressure as the Dutch, as shown by the same
chance of being HEV positive or HEV negative.
Surprisingly, first generation migrants from Turkey
had a lower weighted seroprevalence compared to the
Dutch, although this difference was not significant; yet it
was also significantly lower than that of first generation
Moroccans. This difference is not easily understood. It
indicates that exposure to HEV in Turkey differs from
that in Morocco, however it might also be that the
higher prevalence in Moroccans relative to that of
Turkish first generation migrants in Amsterdam reflects
a more rural versus a more urban descent of these mi-
grants, respectively. The seroprevalence (20.3 %) that we
found in the Turkish group is higher compared to the
seroprevalence estimated in a Turkish study (of 2002)
showing a geographical range of 3.8 % in the city of
Ankara up to more than 15 % in rural Eastern Turkey
[25]. Because the assays that were used differ, study re-
sults are not fully comparable and the Turkish study
possibly underestimated the true prevalence.
Other sero-epidemiological studies in developed coun-
tries reported a wide variety of anti-HEV IgG seropreva-
lence, from 5 % in Japan, to 22 % in France, Germany, and
Denmark and also in the United States [20, 22, 23, 26, 27].
Next to differences in exposure to HEV, an important
issue is also the variation in assays with different perfor-
mances that were used [28–31]. In this study the Wantai
HEV IgG test was used, with a high specificity (99 %) and
sensitivity (98 %) [16, 28, 29, 31–33]. Using this assay the
anti-HEV seroprevalence in many developed countries
was higher than previously anticipated [11, 25, 34].
A limitation of our study is that HEV genotypes are
not known. HEV seropositivity in first generation Mor-
occans may be based on immunity against HEV geno-
types 1 or 2, since these types predominantly circulate in
African countries. Also water-borne HEV outbreaks with
these genotypes have been described in several parts of
Morocco [3, 12, 35]. It might thus well be that first gen-
eration Moroccan participants experienced a HEV infec-
tion before they migrated to the Netherlands, whereas
others got infected in the Netherlands. Due to small
numbers, we were only able to create two age strata in
the analysis of the median age of immigration. Possibly,
residual confounding of age may have influenced our
findings.
In the Netherlands it was previously shown that both
humans and pigs harbor the same HEV genotype 3, so
transmission is probably food-related [14, 15]. Because
Muslims do not eat pork meat or other pork prod-
ucts and because Surinamese people are known not
liking to eat raw or undercooked meat, these groups
may be protected from acquiring HEV genotype 3 in
the Netherlands.
Table 3 Relation between hepatitis E virus IgG and hepatitis A virus IgG seropositivity in Dutch and first generation migrants of the
Amsterdam health monitor study
Anti-HEV IgG positive Anti-HEV IgG negative Total
Ethnicity Na HAV IgG positive % Na HAV IgG positive % Na HAV IgG positive %
Dutch 157 83 52.9 269 123 45.7 426 206 48.4
Moroccan 161 160 99.4 96 91 94.8 257 251 97.7
Turks 99 99 100 197 195 99.0 296 294 99.3
Other 42 32 76.2 178 147 82.6 220 179 81.4
Total 459 374 81.5 740 556 73.1 1199 930 77.6
aN number included
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We hypothesized that because HAV and HEV are both
fecal-orally transmitted infections, there might have
been a relation between the seroprevalence of HEV
and HAV. Almost all first-generation migrants from
Morocco and Turkey had natural immunity to HAV,
regardless of their HEV status. Also within the
Dutch population there was no difference in HAV
status between the anti-HEV IgG positive and nega-
tive groups. Our data showed thus no such relation
between hepatitis E and hepatitis A virus infection
and therefore we think that the transmission of both
hepatitis viruses occurred independently. This was
also previously shown in many other studies. In
most of the countries also the HAV seroprevalence
was higher than the HEV seroprevalence, in similar
age groups [36–40].
Conclusions
In conclusion, the differences in HEV seroprevalence in
people with different ethnic origins may be associated
with a different risk of exposure to HEV in either the
country of origin (migration at a younger age) or in the
Netherlands (migration at older age). More research is
needed on first and second generation migrants to un-
ravel possible cultural and food influences.
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